name: Infliximab and Infliximab Ab Panel:-:Pt:Ser/Plas:-


name: Infliximab and Infliximab Antibody Panel


name: Intensive care unit admission timestamp:TmStp:Pt:^Patient:Qn


name: Intensive care unit discharge timestamp:TmStp:Pt:^Patient:Qn


name: Invasive mechanical ventilation support:Find:Pt:^Patient:Ord


name: Phrenic Nerve Stimulation System Surgical Procedure


name: Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 (0411U)


name: Scientific theories are trustworthy:Find:Pt:^Patient:Ord


name: Scientific theories are weak explanations:Find:Pt:^Patient:Ord


name: Scientific theories are weak explanations


name: Scientist will protect each other even when they are wrong


name: Scientist will protect each other even when they are wrong:Find:Pt:^Patient:Ord


name: Scientists don't care if laypersons understand their work:Find:Pt:^Patient:Ord


name: Scientists don't care if laypersons understand their work


name: Scientists don't value the ideas of others


name: Scientists don't value the ideas of others:Find:Pt:^Patient:Ord


name: Scientists ignore evidence that contradicts their work:Find:Pt:^Patient:Ord


name: Scientists ignore evidence that contradicts their work


name: Scientists intentionally keep their work secret:Find:Pt:^Patient:Ord


name: Scientists intentionally keep their work secret


name: Non-invasive mechanical ventilation support:Find:Pt:^Patient:Ord


name: Karyotype:Presence or Identity:To identify measures at a point in time:Tissue, unspecified^Fetus:Narrative


name: Was there any time when the following kinds of mental health care but could not afford it in the past 12M


name: Was there any time when the following kinds of mental health care but could not afford it in the past 12M:Find:12Mo:^Patient:Ord


name: Was there any time when you needed dental care but could not afford it in past 12M


name: Was there any time when you needed dental care but could not afford it in past 12M:Find:12Mo:^Patient:Ord


name: Was there any time when you needed medical care, but could not afford it in past 12M


name: Was there any time when you needed medical care, but could not afford it in past 12M:Find:12Mo:^Patient:Ord


name: Was there any time when you needed prescribed medicines but could not afford it in last 12M:Find:12Mo:^Patient:Ord


name: Was there any time when you needed prescribed medicines but could not afford it in last 12M


name: We can trust science to find the answers that explain the natural world


name: We can trust science to find the answers that explain the natural world:Find:Pt:^Patient:Ord


name: We can trust scientists to share their discoveries even if they don't like their findings:Find:Pt:^Patient:Ord


name: We can trust scientists to share their discoveries even if they don't like their findings


name: We cannot trust science because it moves too slowly:Find:Pt:^Patient:Ord


name: We cannot trust science because it moves too slowly


name: We cannot trust scientists because they are biased in their perspectives


name: We cannot trust scientists because they are biased in their perspectives:Find:Pt:^Patient:Ord


name: We cannot trust scientists to consider ideas that contradict their own:Find:Pt:^Patient:Ord


name: We cannot trust scientists to consider ideas that contradict their own


name: We should trust that scientists are being ethical in their work:Find:Pt:^Patient:Ord


name: We should trust that scientists are being ethical in their work


name: We should trust that scientists are being honest in their work:Find:Pt:^Patient:Ord


name: We should trust that scientists are being honest in their work


name: We should trust the work of scientists:Find:Pt:^Patient:Ord


name: Follow the vaccinated-tested-recovered rule last 2W


name: Follow the vaccinated-tested-recovered rule last 2W:Find:Pt:^Patient:Nom


name: Were you obliged to wear masks in closed public areas in last 2W


name: Were you obliged to wear masks in closed public areas in last 2W:Find:2W:^Patient:Ord


name: Were you obliged to wear masks in open public areas in last 2W:Find:Pt:^Patient:Ord


name: Were you obliged to wear masks in open public areas in last 2W


name: What would you say how is the mental health of your partner is:Find:Pt:^Patient:Ord


name: Time interval between troponin I.high-sensitivity assays:Time:Pt:^Patient:Qn


name: Time interval between troponin I.high-sensitivity assays


name: Today's scientists will sacrifice the well-being of others to advance their research:Find:Pt:^Patient:Ord


name: Today's scientists will sacrifice the well-being of others to advance their research


name: Trust in Science and Scientist Inventory


name: Trust in Science and Scientist Inventory:-:Pt:^Patient:-


name: Type of mechanical circulatory support:Find:Pt:^Patient:Nom


name: Unmet Healthcare Needs panel:-:Pt:^Patient:-


name: What would you say is the quality of your partnership


name: What would you say how is the mental health of your partner is


name: What would you say is the quality of your partnership:Find:Pt:^Patient:Ord


name: When contacting people outside of household have you kept a minimum of 1.5 to 2 meters away:Find:Pt:^Patient:Ord


name: When contacting people outside of household have you kept a minimum of 1.5 to 2 meters away


name: When scientists change their mind about a scientific idea it diminishes my trust in their work:Find:Pt:^Patient:Ord


name: When scientists change their mind about a scientific idea it diminishes my trust in their work


name: When scientists form a hypothesis they are just guessing


name: When scientists form a hypothesis they are just guessing:Find:Pt:^Patient:Ord


name: Which household type do you live in:Find:Pt:^Patient:Ord


name: Exposure to hexamethylene diisocyanate (event)


name: Pediatric Canadian Triage and Acuity Scale score


name: Pediatric Canadian Triage and Acuity Scale


name: Any administered antiepileptics [Anticonvulsants]:Find:Pt:^Patient:Ord


name: Any administered antiepileptics [Anticonvulsants]


name: Are underage people living in household:Find:Pt:^Patient:Ord


name: Are you in a committed relationship:Find:Pt:^Patient:Ord


name: Bile acid malabsorption panel:-:Pt:^Patient:-


name: {2 (0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector [Yuflyma]) / 1 (0.8 ML adalimumab-aaty 100 MG/ML Auto-Injector [Yuflyma]) } Pack [Yuflyma Auto-Injector 80 MG/0.8 ML and 40 MG/0.4 ML Starter Pack - Plaque Psoriasis]


name: Cat epithelium Ab.IgE panel:-:Pt:Ser/Plas:-


name: Certificate of medical necessity:Find:Pt:^Patient:Doc


name: Childcare from a provider or person outside the household was available in 2020


name: Childcare from a provider or person outside the household was available in 2020:Find:Pt:^Patient:Ord


name: Childcare from a provider or person outside the household was available in past 3M:Find:Pt:^Patient:Ord


name: Childcare from a provider or person outside the household was available in past 3M


name: Children and work family balance panel:-:Pt:^Patient:-


name: Confusion, disorientation or impulsivity:Find:Pt:^Patient:Ord


name: Did you work remotely at home completely or only on several D per W during last 2W


name: Did you work remotely at home completely or only on several D per W during last 2W:Find:2W:^Patient:Ord


name: Do you feel physically or emotionally unsafe where you currently live:-:Pt:^Patient:-:SDOH


name: Do you feel physically or emotionally unsafe where you currently live


name: Do you have a food insecurity:-:Pt:^Patient:-:SDOH


name: Do you have a housing insecurity:-:Pt:^Patient:-:SDOH


name: Do you have a personal safety insecurity


name: Do you have a personal safety insecurity:-:Pt:^Patient:-:SDOH


name: Do you have a travel insecurity:-:Pt:^Patient:-:SDOH


name: Do you have underage persons in your household


name: Do you have underage persons in your household:Find:Pt:^Patient:Ord


name: Do you have utilities insecurity:-:Pt:^Patient:-:SDOH


name: Domestic violence screening report:Find:Pt:{Setting}:Doc


name: Durable medical equipment proof of delivery receipt


name: Durable medical equipment proof of delivery receipt:Find:Pt:^Patient:Doc


name: child and adolescent psychiatry education note


name: drainage of left sphenoid sinus (treatment)


name: drainage of right sphenoid sinus (treatment)


name: nutrition and dietetics risk assessment and screening note


name: occlusion of left renal artery (treatment)


name: occlusion of right renal artery (treatment)


name: oxygen saturation in arterial blood by pulse oximetry


name: surgery telephone encounter consult note


name: occlusion of external iliac artery (treatment)


name: occlusion of common iliac artery (treatment)


name: occlusion of popliteal artery (treatment)


name: occlusion of subclavian artery (treatment)


name: occlusion of innominate vein (treatment)


name: occlusion of brachial artery (treatment)


name: occlusion of vertebral artery (treatment)


name: occlusion of internal jugular vein (treatment)


name: occlusion of subclavian vein (treatment)


name: Removal of foreign body from alveolar process


name: occlusion of inferior mesenteric artery (treatment)


name: occlusion of left subclavian artery (treatment)


name: Annotation type (foundation metadata concept)


name: CALCIPOTRIENE 0.005%/DIMETHICONE 5% CREAM,TOP KIT


name: Janus-associated kinase (JAK) inhibitors (L04AF)


name: Killip classification (assessment scale)


name: Language code (foundation metadata concept)


name: Mammalian target of rapamycin (mTOR) kinase inhibitors (L04AH)


name: Constructive Interference In Steady State


name: National Marrow Donor Program Modified Toxicity Criteria


name: Building and Grounds Cleaning and Maintenance Occupations


name: Allogeneic Pancreatic Islet Cellular Therapy [EPC]


name: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]


name: Bispecific CD20-directed CD3 T Cell Engager [EPC]


name: Nicotinamide Modified Allogeneic Hematopoietic Progenitor Cell Therapy [EPC]


name: Allogeneic Cellularized Scaffold Cell Therapy [EPC]


name: CD19-directed Genetically Modified Autologous T Cell Immunotherapy [EPC]


name: uman Immunodeficiency Virus 1 Capsid Inhibitor [EPC]


name: gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]


name: Herpes Simplex Virus Type 1 Vector-based Gene Therapy [EPC]


name: Adeno-associated Virus Vector-based Gene Therapy [EPC]


name: B-cell Maturation Antigen-directed Genetically Modified Autologous T Cell Immunotherapy [EPC]


name: Adenovirus Vector-Based Gene Therapy [EPC]


name: Allogeneic Processed Thymus Tissue-based Immunotherapy [EPC]


name: Bmi documented outside normal parameters, no follow-up plan documented, no reason given (M1276)


name: Bmi not documented and no reason is given (M1314)


name: Influenza immunization administered or previously received (M1299)


name: Women who had a bilateral mastectomy or who have a history of a bilateral mastectomy or for whom there is evidence of a right and a left unilateral mastectomy (M1280)


name: Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason (M1286)


name: Patient not screened for tobacco use (M1312)


name: Patient identified as tobacco user did not receive tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) (M1289)


name: Documentation stating the patient has received or is currently receiving palliative or hospice care (M1307)


name: Tobacco screening not performed or tobacco cessation intervention not provided during the measurement period or in the six months prior to the measurement period (M1313)


name: Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period (M1305)


name: Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period (G9991)


name: Patients who died during the measurement period (M1362)


name: Patients who died during the measurement period (M1356)


name: Blood pressure reading not documented, reason not given (M1281)


name: Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified (M1285)


name: Itch severity assessment score is reduced by 3 or more points from the initial (index) assessment score to the follow-up visit score (M1205)


name: Itch severity assessment score is reduced by 3 or more points from the initial (index) assessment score to the follow-up visit score (M1197)


name: Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) (M1301)


name: Patients age 66 or older in institutional special needs plans (snp) or residing in long term care with pos code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period (M1284)


name: Bmi is documented above normal parameters and a follow-up plan is documented (M1293)


name: Bmi is documented below normal parameters and a follow-up plan is documented (M1287)


name: Normal blood pressure reading documented, follow-up not required (M1294)


name: Itch severity assessment score was not reduced by at least 3 points from initial (index) score to the follow-up visit score or assessment was not completed during the follow-up encounter (M1206)


name: Itch severity assessment score was not reduced by at least 3 points from initial (index) score to the follow-up visit score or assessment was not completed during the follow-up encounter (M1198)


name: Gradient compression arm sleeve and glove combination, custom, each (A6574)


name: Influenza immunization was not administered, reason not given (M1308)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (M1291)


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use


name: Bmi is documented within normal parameters and no follow-up plan is required (M1296)


name: Hospice services provided to patient any time during the measurement period (M1303)


name: Patient not eligible due to active diagnosis of hypertension (M1290)


name: Patient screened for tobacco use and identified as a tobacco non-user (M1282)


name: Anaphylaxis due to the vaccine on or before the date of the encounter


name: Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given (M1279)


name: Documented reason for not screening or recommending a follow-up for high blood pressure (M1288)


name: Documentation of patient pregnancy anytime during the measurement period prior to and including the current encounter (M1298)


name: Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user (M1310)


name: Patient had anaphylaxis due to the pneumococcal vaccine any time during or before the measurement period


name: {14 (valbenazine 40 MG Oral Capsule [Ingrezza]) / 14 (valbenazine 60 MG Oral Capsule [Ingrezza]) } Pack [Ingrezza 40/60 Initiation Pack]


name: Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) (M1300)


name: Patient screened for tobacco use and identified as a tobacco user (M1283)


name: Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up) (M1335)


name: Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up) (M1330)


name: Suicide risk based on their clinician's evaluation or a clinician-rated tool (M1361)


name: Suicide risk based on their clinician's evaluation or a clinician-rated tool (M1355)


name: Bmi not documented due to medical reason or patient refusal of height or weight measurement (M1297)


name: Screening, diagnostic, film digital or digital breast tomosynthesis (3d) mammography results documented and reviewed (M1302)


name: Mandibular advancement device application


name: Cardiac pharmacologic stress test abnormal


name: Mandibular orthopaedic repositioning appliance application


name: Hypofractionated stereotactic radiation therapy


name: Proximal femoral nail antirotation insertion


name: Gene-based urine test for bladder cancer


name: Cytobacteriological examination of urine


name: Peripheral bronchoscopy with radial probe endobronchial ultrasound


name: Rest, ice, compression and elevation method


name: False negative radioisotope investigation result


name: Granulocyte-colony stimulating factor test


name: Biliopancreatic diversion with duodenal switch


name: Lipoprotein-associated phospholipase A2 increased


name: Human parainfluenza virus type 1 test negative


name: Human parainfluenza virus type 2 test negative


name: Human parainfluenza virus type 4 test negative


name: Human parainfluenza virus type 3 test negative


name: Surgical resection of buccal mucosa neoplasm


name: Pedicled pectoralis major myocutaneous flap surgery


name: Direct arthroscopic distal clavicle resection


name: Chemokine (C-C motif) ligand 17 increased


name: Ventricular septum thickness measurement


name: Medial collateral ligament reconstruction


name: Puncture, aspiration, injection, and reaspiration technique


name: Cornell assessment of paediatric delirium score


name: Whipple procedure with superior mesenteric vein resection


name: Wave reflector breast lesion localisation


name: Human epidermal growth factor receptor positive


name: Laparoscopic left lateral hepatic sectionectomy


name: Cervical liquid-based thin-layer cell smear


name: Hormonal intra-uterine contraceptive device insertion


name: Implant-supported dental bridge placement


name: Reduced circulating reticulated platelet count


name: Replication competent lentivirus test positive


name: Decreased prothrombin time percentage activity


name: Unintentional therapeutic error with medication


name: CAR transgene level with predominant insertion site quantification


name: CAR transgene level with predominant insertion site elevated


name: Unintentional exposure to product by child


name: occlusion of right subclavian artery (treatment)


name: occlusion of intracranial artery (treatment)


name: Carmex Daily Care Moisturizing Lip Balm Free Cupcake Batter Stick Sunscreen SPF 15 KIT


name: Carmex Daily Care Moisturizing Lip Balm Sunscreen SPF 15 KIT


name: Carmex Daily Care Moisturizing Lip Balm SPF 15 Sunscreen Minis KIT


name: Carmex 10 Count Variety Pack SPF 15 Sunscreen KIT


name: ALUMINUM SESQUICHLOROHYDRATE 220 mg in 1 mL TOPICAL STICK [Power Stick For Her Roll- On Antiperspirant Deodorant Powder Fresh]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL TOPICAL LOTION


name: HOMOSALATE 150 mg in 1 g / OCTISALATE 50 mg in 1 g / OCTOCRYLENE 100 mg in 1 g / AVOBENZONE 30 mg in 1 g TOPICAL STICK [Neutrogena Beach Defense Kids Sunscreen SPF 60 Plus]


name: PHENOXYETHANOL 1.8 g in 200 mL / FRAGRANCE 13576 0.8 g in 200 mL / ETHYLHEXYLGLYCERIN 0.2 g in 200 mL / AVOBENZONE 2 g in 200 mL / .BETA.-SITOSTEROL 0.01 g in 200 mL / HYDROLYSED MARINE COLLAGEN (ENZYMATIC; 2000 MW) 0.2 g in 200 mL / LINOLEIC ACID 0.16 g in 200 mL / TOCOPHEROL 0.08 g in 200 mL / MALVA SYLVESTRIS FLOWERING TOP 0.06 g in 200 mL / PAPAVER RHOEAS FLOWER 0.04 g in 200 mL / MEDIUM-CHAIN TRIGLYCERIDES 34 g in 200 mL / SHEA BUTTER 4 g in 200 mL / LINOLENIC ACID 0.04 g in 200 mL / POLYGLYCERYL-4 ISOSTEARATE 3 g in 200 mL / HEXYL LAURATE 2.7 g in 200 mL / WHITE WAX 1 g in 200 mL / HYDROGENATED CASTOR OIL 4 g in 200 mL / AMILOXATE 4 g in 200 mL / CETYL PEG/PPG-10/1 DIMETHICONE (HLB 4) 3 g in 200 mL / SQUALANE 0.01 g in 200 mL / WATER 125.88 g in 200 mL / GLYCERIN 7 g in 200 mL / CETEARYL ETHYLHEXANOATE 4 g in 200 mL TOPICAL CREAM [Anubis Barcelona Vital Line]


name: ZINC OXIDE 200 mg in 1 g TOPICAL LOTION [Baby Mineral Sunscreen SPF55]


name: ZINC OXIDE 200 mg in 1 g TOPICAL LOTION [Mineral Sunscreen SPF 50]


name: ZINC OXIDE 25 g in 100 mL TOPICAL LOTION [goPure Sunscreen]


name: ZINC OXIDE 175.3 mg in 1 mL TOPICAL LOTION [Hero Force Shield Superbeam Sunscreen SPF 30 Apricot]


name: BENZOCAINE 7.5 g in 100 mL TOPICAL CREAM [ANAL-ESE]


name: BENZOCAINE 7.5 g in 100 mL TOPICAL CREAM [Anal Blu]


name: CITRIC ACID MONOHYDRATE 0.3 g in 100 mL HEMODIALYSIS SOLUTION, CONCENTRATE [AQUACETIC-30]


name: CITRIC ACID MONOHYDRATE 0.5 g in 100 mL HEMODIALYSIS SOLUTION, CONCENTRATE [CITRACID-50]


name: ZINC OXIDE 4.93 mg in 50 mL / OCTINOXATE 3.75 mg in 50 mL TOPICAL CREAM [Dr Lift SPF 50 Cream]


name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Vaihea Protect Clean SPF Drops]


name: {1 (acetaminophen 325 MG / dextromethorphan hydrobromide 10 MG / doxylamine succinate 6.25 MG Oral Capsule) / 1 (acetaminophen 325 MG / dextromethorphan hydrobromide 10 MG Oral Capsule) } Pack


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTOCRYLENE 6 g in 100 g TOPICAL LOTION [Rubber Ducky SPF 50 Unfragranced Sunscreen]


name: ZINC OXIDE 150 mg in 1 mL TOPICAL LIQUID [Eminence Radiant Protection SPF Fluid]


name: FRAGRANCE 13576 0.15 g in 50 mL / GRAPE SEED OIL 0.25 g in 50 mL / GLYCERYL MONOSTEARATE 3.5 g in 50 mL / LINALOOL, (+/-)- 0.0114 g in 50 mL / PHENOXYETHANOL 0.45 g in 50 mL / PROPYLENE GLYCOL 1.5 g in 50 mL / TITANIUM DIOXIDE 0.25 g in 50 mL / PALMITIC ACID 1 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.25 g in 50 mL / STARCH, RICE 5.5 g in 50 mL / ALCOHOL 4.752 mL in 50 mL / C12-20 ACID PEG-8 ESTER 1 g in 50 mL / TROLAMINE 0.25 g in 50 mL / ISOMETHYL-.ALPHA.-IONONE 0.00639 g in 50 mL / HYDROXYACETOPHENONE 0.25 g in 50 mL / PERLITE 4 g in 50 mL / GLYCERIN 0.0115 g in 50 mL / ETHYLHEXYLGLYCERIN 0.05 g in 50 mL / .BETA.-CITRONELLOL, (R)- 0.012 g in 50 mL / WATER 25.04945 g in 50 mL / STEARIC ACID 1 g in 50 mL / CETEARYL ETHYLHEXANOATE 0.75 g in 50 mL TOPICAL CREAM [Anubis Barcelona Spa Line]


name: OCTINOXATE 3.5982 g in 50 mL / TITANIUM DIOXIDE 0.425 g in 50 mL / CHLORPHENESIN 0.1 g in 50 mL / OCTISALATE 1.8 g in 50 mL / BUTYLENE GLYCOL 2.5 g in 50 mL / PROPYLENE GLYCOL 2.5 g in 50 mL / POLY(METHYL METHACRYLATE; 450000 MW) 2.1 g in 50 mL / WATER 27.55 mL in 50 mL / SILICON DIOXIDE 0.575 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.0018 g in 50 mL / DIMETHICONE 1.25 g in 50 mL / CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE 0.025 g in 50 mL / C20-22 ALCOHOLS 0.3375 g in 50 mL / FRAGRANCE 13576 0.3 g in 50 mL / CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) 0.075 g in 50 mL / TROMETHAMINE 0.22 g in 50 mL / BEMOTRIZINOL 1.45 g in 50 mL / POLYETHYLENE GLYCOL 400 0.14225 g in 50 mL / ASCORBYL PALMITATE 0.00125 g in 50 mL / PHENOXYETHANOL 0.35 g in 50 mL / OCTOCRYLENE 1.8 g in 50 mL / AVOBENZONE 1.8 g in 50 mL / LINOLENIC ACID 0.00275 g in 50 mL / ASCORBIC ACID 0.00025 g in 50 mL / TOCOPHEROL 0.006 g in 50 mL / LINOLEIC ACID 0.49725 g in 50 mL / GLYCERIN 0.005 g in 50 mL TOPICAL CREAM [Anubis Barcelona Protective Line]


name: ALOE VERA LEAF 5.988 g in 60 mL / LINALOOL, (+/-)- 0.0006 g in 60 mL / EUGENOL 0.0006 g in 60 mL / PROPANEDIOL 2.496 g in 60 mL / BENZYL ALCOHOL 0.456 g in 60 mL / CETOSTEARYL ALCOHOL 1.2 g in 60 mL / DICAPRYLYL ETHER 1.5 g in 60 mL / SORBIC ACID 0.024 g in 60 mL / XANTHAN GUM 0.18 g in 60 mL / .BETA.-CITRONELLOL, (R)- 0.0006 g in 60 mL / GLYCERYL MONOSTEARATE 2.4 g in 60 mL / FRAGRANCE 13576 0.114 g in 60 mL / SALICYLIC ACID 0.09 g in 60 mL / JUJUBE SEED 0.048 g in 60 mL / LECITHIN, SOYBEAN 0.036 g in 60 mL / BAICALIN 0.012 g in 60 mL / LEUZEA CARTHAMOIDES ROOT 0.012 g in 60 mL / WATER 33.2616 mL in 60 mL / LIMONENE, (+)- 0.006 g in 60 mL / HYDROXYCITRONELLAL 0.0024 g in 60 mL / TOCOPHEROL 0.0018 g in 60 mL / GLYCERIN 3.036 g in 60 mL / DECYL OLEATE 3.9 g in 60 mL / SHEA BUTTER 2.1 g in 60 mL TOPICAL CREAM [Anubis Barcelona]


name: FD&C BLUE NO. 1 0.0005 g in 250 mL / LACTIC ACID 2.348125 g in 250 mL / POLYOXYL 40 HYDROGENATED CASTOR OIL 1.25 g in 250 mL / TROLAMINE 0.5 g in 250 mL / .ALPHA.-HEXYLCINNAMALDEHYDE 0.0150375 g in 250 mL / LINALOOL, (+/-)- 0.0041025 g in 250 mL / BENZOIC ACID 0.625 g in 250 mL / PHENOXYETHANOL 2.5 g in 250 mL / GLYCOLIC ACID 1.220625 g in 250 mL / WATER 228.15635 mL in 250 mL / ALLANTOIN 0.75 g in 250 mL / DEHYDROACETIC ACID 0.25 g in 250 mL / DIETHYLENE GLYCOL MONOETHYL ETHER 0.75 g in 250 mL / FRAGRANCE 13576 0.075 g in 250 mL / LIMONENE, (+)- 0.022755 g in 250 mL / PROPYLENE GLYCOL 10.5 g in 250 mL TOPICAL LOTION [Anubis Barcelona New Even]


name: GLYCERIN 0.01035 g in 1.5 mL / PHENOXYETHANOL 0.0003 g in 1.5 mL / FRAGRANCE 13576 0.00285 g in 1.5 mL / DEHYDROACETIC ACID 0.00135 g in 1.5 mL / WATER 1.16659425 mL in 1.5 mL / PEG-8 CAPRYLIC/CAPRIC GLYCERIDES 0.15 g in 1.5 mL / ISOMETHYL-.ALPHA.-IONONE 0.00003 g in 1.5 mL / EDETIC ACID 0.000009 g in 1.5 mL / BENZOIC ACID 0.0009 g in 1.5 mL / SORBIC ACID 0.0006 g in 1.5 mL / BENZYL ALCOHOL 0.01215 g in 1.5 mL / PROPANEDIOL 0.15 g in 1.5 mL / HYDROXYCITRONELLAL 0.00006 g in 1.5 mL TOPICAL CONCENTRATE [Anubis Barcelona]


name: GLYCERIN 0.08784 g in 200 mL / GERANIOL 0.003398 g in 200 mL / ISOPROPYL ALCOHOL 0.002132 g in 200 mL / ALCOHOL 3.5436 mL in 200 mL / OXYBENZONE 1.6 g in 200 mL / PHENOXYETHANOL 1.3 g in 200 mL / TEA TREE OIL 0.1 g in 200 mL / IMIDUREA 0.4 g in 200 mL / WATER 155.839258 mL in 200 mL / GLYCERYL STEARATE SE 6 g in 200 mL / CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE 0.8 g in 200 mL / TIOXOLONE 0.3 g in 200 mL / LINALOOL, (+/-)- 0.026404 g in 200 mL / FD&C YELLOW NO. 5 0.01044 g in 200 mL / BENZYL BENZOATE 0.004 g in 200 mL / PANTHENOL 0.04 g in 200 mL / COUMARIN 0.003924 g in 200 mL / C12-20 ACID PEG-8 ESTER 4 g in 200 mL / ARCTIUM LAPPA ROOT 0.003512 g in 200 mL / PROPYLPARABEN 0.28 g in 200 mL / CETYL ALCOHOL 0.015 g in 200 mL / YEAST, UNSPECIFIED 0.1 g in 200 mL / RIBOFLAVIN 0.00012 g in 200 mL / PROPYLENE GLYCOL 6.469044 g in 200 mL / CETEARYL ETHYLHEXANOATE 10 g in 200 mL / HYDROXYETHYL CELLULOSE, UNSPECIFIED 0.12863 g in 200 mL / BUTYLATED HYDROXYTOLUENE 0.104 g in 200 mL / CITRAL 0.01032 g in 200 mL / GREEN TEA LEAF 0.00679 g in 200 mL / ALLANTOIN 0.2 g in 200 mL / LIMONENE, (+)- 0.061818 g in 200 mL / NIACINAMIDE 0.02 g in 200 mL / POWDERED CELLULOSE 0.001066 g in 200 mL / POLYOXYL 40 HYDROGENATED CASTOR OIL 1.8 g in 200 mL / .ALPHA.-HEXYLCINNAMALDEHYDE 0.00574 g in 200 mL / OCTINOXATE 3.996 g in 200 mL / METHYLPARABEN 0.6 g in 200 mL / FRAGRANCE 13576 0.5 g in 200 mL TOPICAL CREAM [Anubis Barcelona Regul Oil]


name: GLYCERIN 0.555 g in 30 mL / PHENOXYETHANOL 0.243 g in 30 mL / XANTHAN GUM 0.09 g in 30 mL / FRAGRANCE 13576 0.027 g in 30 mL / SORBITAN ISOSTEARATE 0.024 g in 30 mL / HYDROLYZED BOVINE ELASTIN (BASE; 1000 MW) 0.0012 g in 30 mL / LIMONENE, (+)- 0.0009 g in 30 mL / TOCOPHEROL 0.0003 g in 30 mL / HYDROXYCITRONELLAL 0.0006 g in 30 mL / POLYSORBATE 60 0.024 g in 30 mL / LECITHIN, SOYBEAN 0.45 g in 30 mL / HYDROXYETHYL ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE COPOLYMER (100000 MPA.S AT 1.5%) 0.405 g in 30 mL / DEHYDROACETIC ACID 0.021 g in 30 mL / PROPANEDIOL 1.08 g in 30 mL / DICAPRYLYL ETHER 0.9 g in 30 mL / BENZOIC ACID 0.036 g in 30 mL / ASCORBYL GLUCOSIDE 0.15 g in 30 mL / WATER 25.5564 mL in 30 mL TOPICAL CONCENTRATE [Anubis Barcelona]


name: ALCOHOL 3.512 mL in 10 mL / POLYOXYL 40 HYDROGENATED CASTOR OIL 0.04 g in 10 mL / YEAST, UNSPECIFIED 0.0345 g in 10 mL / PROPYLENE GLYCOL 0.0138 g in 10 mL / ARCTIUM LAPPA ROOT 0.00007 g in 10 mL / ALLANTOIN 0.025 g in 10 mL / POWDERED CELLULOSE 0.0006 g in 10 mL / PROPYLPARABEN 0.0000002 g in 10 mL / TOCOPHEROL 0.000002 g in 10 mL / FRAGRANCE 13576 0.02 g in 10 mL / ETHYLPARABEN 0.0000003 g in 10 mL / ASCORBYL PALMITATE 0.0001 g in 10 mL / WATER 6.2503117 mL in 10 mL / TIOXOLONE 0.02 g in 10 mL / LEVOMENOL 0.009 g in 10 mL / HYDROXYETHYL CELLULOSE, UNSPECIFIED 0.034 g in 10 mL / ISOPROPYL ALCOHOL 0.0012 g in 10 mL / FARNESOL 0.001 g in 10 mL / METHYLPARABEN 0.0100013 g in 10 mL / PANTHENOL 0.005 g in 10 mL / PHENOXYETHANOL 0.000006 g in 10 mL / BUTYLPARABEN 0.0000005 g in 10 mL / NIACINAMIDE 0.0002 g in 10 mL / RIBOFLAVIN 0.000006 g in 10 mL / CITRAL 0.000194 g in 10 mL / LIMONENE, (+)- 0.00419 g in 10 mL / FD&C YELLOW NO. 5 0.00002 g in 10 mL TOPICAL CONCENTRATE [Anubis Barcelona Regul OIl]


name: ALCOHOL 52.5 mL in 250 mL / NIACINAMIDE 0.025 g in 250 mL / TIOXOLONE 0.25 g in 250 mL / ARCTIUM LAPPA ROOT 0.0225 g in 250 mL / RIBOFLAVIN 0.0025 g in 250 mL / POLYOXYL 40 HYDROGENATED CASTOR OIL 2 g in 250 mL / METHYLPARABEN 0.5 g in 250 mL / YEAST, UNSPECIFIED 0.14375 g in 250 mL / FD&C YELLOW NO. 5 0.0015 g in 250 mL / GLYCERIN 0.45 g in 250 mL / FRAGRANCE 13576 0.5 g in 250 mL / WATER 179.89815 mL in 250 mL / PANTHENOL 0.05 g in 250 mL / LIMONENE, (+)- 0.10475 g in 250 mL / ALLANTOIN 0.25 g in 250 mL / CITRAL 0.00485 g in 250 mL / PROPYLENE GLYCOL 13 g in 250 mL TOPICAL LOTION [Anubis Barcelona Regul Oil]


name: ARCTIUM LAPPA ROOT 0.012 g in 200 mL / POLYACRYLAMIDE (CROSSLINKED; 0.01-0.2 MOLE PERCENT BISACRYLAMIDE) 0.8 g in 200 mL / LAURETH-7 0.12 g in 200 mL / PEG/PPG-20/6 DIMETHICONE 1.372 g in 200 mL / ALCOHOL 0.08 mL in 200 mL / GLYCERIN 0.048 g in 200 mL / CETEARYL ETHYLHEXANOATE 4 g in 200 mL / LIMONENE, (+)- 0.08398 g in 200 mL / PANTHENOL 0.1 g in 200 mL / IMIDUREA 0.6 g in 200 mL / FD&C YELLOW NO. 5 0.00004 g in 200 mL / RIBOFLAVIN 0.00012 g in 200 mL / PHENOXYETHANOL 0.0252 g in 200 mL / FRAGRANCE 13576 0.6 g in 200 mL / WATER 123.55598 mL in 200 mL / CETOSTEARYL ALCOHOL 26 g in 200 mL / PROPYLENE GLYCOL 10.148 g in 200 mL / MINERAL OIL 6 g in 200 mL / ETHYLHEXYLGLYCERIN 0.0028 g in 200 mL / METHYLCHLOROISOTHIAZOLINONE 0.045 g in 200 mL / METHYLISOTHIAZOLINONE 0.15 g in 200 mL / HOPS 0.0012 g in 200 mL / TIOXOLONE 0.3 g in 200 mL / PROPYLPARABEN 0.24 g in 200 mL / YEAST, UNSPECIFIED 0.023 g in 200 mL / NIACINAMIDE 0.023 g in 200 mL / C13-14 ISOPARAFFIN 0.48 g in 200 mL / METHYLPARABEN 0.48 g in 200 mL / GLYCERYL STEARATE SE 7 g in 200 mL / TRIISOPROPANOLAMINE 0.004 g in 200 mL / PENTAERYTHRITOL TETRAKIS(3-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)PROPIONATE) 0.0012 g in 200 mL TOPICAL CREAM [Anubis Barcelona Regul Oil]


name: BETAINE 5 g in 250 mL / FRAGRANCE 13576 0.125 g in 250 mL / FD&C BLUE NO. 1 0.00025 g in 250 mL / BENZOIC ACID 1.75 g in 250 mL / GLYCERIN 5 g in 250 mL / PHENOXYETHANOL 2.25 g in 250 mL / ETHYLHEXYLGLYCERIN 0.125 g in 250 mL / POLYSORBATE 20 2.75 g in 250 mL / WATER 232.139 mL in 250 mL / IMIDUREA 0.75 g in 250 mL TOPICAL LOTION [Anubis Barcelona Total Hydrating]


name: PHENOXYETHANOL 0.162 g in 20 mL / XANTHAN GUM 0.08 g in 20 mL / BENZOIC ACID 0.024 g in 20 mL / WATER 16.4578 mL in 20 mL / BUTYLENE GLYCOL 0.46 g in 20 mL / PROPANEDIOL 0.4 g in 20 mL / POLYSORBATE 20 0.2 g in 20 mL / EDETIC ACID 0.0002 g in 20 mL / PROTEOGLYCAN 4 0.002 g in 20 mL / FRAGRANCE 13576 0.03 g in 20 mL / GLYCERIN 2 g in 20 mL / DEHYDROACETIC ACID 0.014 g in 20 mL TOPICAL CONCENTRATE [Anubis Barcelona]


name: PROPYLPARABEN 0.0000001 g in 5 mL / ALLANTOIN 0.0125 g in 5 mL / PANTHENOL 0.0025 g in 5 mL / FD&C YELLOW NO. 5 0.00001 g in 5 mL / PROPYLENE GLYCOL 0.0069 g in 5 mL / ARCTIUM LAPPA ROOT 0.000035 g in 5 mL / METHYLPARABEN 0.00500065 g in 5 mL / TIOXOLONE 0.01 g in 5 mL / WATER 3.12515585 mL in 5 mL / ALCOHOL 1.756 mL in 5 mL / POLYOXYL 40 HYDROGENATED CASTOR OIL 0.02 g in 5 mL / YEAST, UNSPECIFIED 0.01725 g in 5 mL / ASCORBYL PALMITATE 0.00005 g in 5 mL / RIBOFLAVIN 0.000003 g in 5 mL / ETHYLPARABEN 0.00000015 g in 5 mL / TOCOPHEROL 0.000001 g in 5 mL / CITRAL 0.000097 g in 5 mL / LIMONENE, (+)- 0.002095 g in 5 mL / POWDERED CELLULOSE 0.0003 g in 5 mL / ISOPROPYL ALCOHOL 0.0006 g in 5 mL / HYDROXYETHYL CELLULOSE, UNSPECIFIED 0.017 g in 5 mL / LEVOMENOL 0.0045 g in 5 mL / FARNESOL 0.0005 g in 5 mL / FRAGRANCE 13576 0.01 g in 5 mL / PHENOXYETHANOL 0.000003 g in 5 mL / BUTYLPARABEN 0.00000025 g in 5 mL / NIACINAMIDE 0.0001 g in 5 mL TOPICAL CONCENTRATE [Anubis Barcelona]


name: Levomefolate Calcium/Pyridoxal Phosphate/Mecobalamin/Algal, Vitamin B Complex oral capsule


name: Eucerin Advanced Repair Moisturizing Foam


name: Eucerin Sensitive Mineral Face Protection


name: Extended Infusion Set 6mm Cannula 23" Tubing


name: Extended Infusion Set 9mm Cannula 23" Tubing


name: Extended Infusion Set 9mm Cannula 32" Tubing


name: Nivea Deep Nourishing Serum and Almond Oil


name: Nivea Lip Care Dewy Plus Hyaluronic Acid


name: Nivea Men Sensitive Calm Face and Beard Balm


name: Nivea Skin Toning and Firming Body Gel Cream


name: Skin-EEZ 10-20mmHg Compression Sock L/XL


name: Skin-EEZ 10-20mmHg Compression Sock S/M Black


name: Skin-EEZ 10-20mmHg Compression Sock S/M Tan


name: Skin-EEZ 10-20mmHg Compression Sock S/M White


name: Skin-EEZ 10-20mmHg Compression Socks L/XL Tan


name: Skin-EEZ 20-30mmHg Compression Sock S/M Black


name: Skin-EEZ 20-30mmHg Compression Sock S/M White


name: Skin-EEZ 20-30mmHg Compression Socks L/XL


name: Skin-EEZ 20-30mmHg Compression Socks L/XL Tan


name: Skin-EEZ 20-30mmHg Compression Socks S/M Tan


name: Skin-EEZ 30-40mmHg Compression Sock L/XL


name: Skin-EEZ 30-40mmHg Compression Sock S/M Black


name: Skin-EEZ 30-40mmHg Compression Sock S/M White


name: Skin-EEZ 30-40mmHg Compression Socks L/XL Tan


name: Skin-EEZ 30-40mmHg Compression Socks S/M Tan


name: Skin-EEZ Anti-Embolism Knee High L/XL White


name: Skin-EEZ Anti-Embolism Knee High S/M White


name: Skin-EEZ Anti-Embolism Thigh High L White


name: Skin-EEZ Anti-Embolism Thigh High L/XL White


name: Skin-EEZ Anti-Embolism Thigh High M White


name: Skin-EEZ Anti-Embolism Thigh High S White


name: Skin-EEZ Anti-Embolism Thigh High XL White


name: Skin-EEZ Anti-Embolism Thigh Length S/M White


name: Skin-EEZ Anti-Embolism Thigh Length White L


name: Skin-EEZ Arthritis Compression Gloves Unisex


name: Skin-EEZ Compression Foot Ankle Sleeve L/XL


name: Skin-EEZ Compression Foot Ankle Sleeve S/M


name: Skin-EEZ Diabetic Healing Socks L/XL Black


name: Skin-EEZ Diabetic Healing Socks L/XL White


name: Skin-EEZ Diabetic Healing Socks S/M Black


name: Skin-EEZ Diabetic Healing Socks S/M White


name: Cleanser Topical application Soap [Nivea Men Active Clean Body Wash]


name: Stick, Multi Ingredient Topical application Stick [Nivea Dewy Lip Care]


name: Foam, Multi Ingredient Topical application Foam [Eucerin Leg & Foot]


name: Cream, Multi Ingredient Topical application Cream [Eucerin Face Skin Balance Night Cream]


name: Lotion, Multi Ingredient Topical application Lotion [Eucerin After Sun]


name: Cream, Multi Ingredient Topical application Cream [Eucerin Advanced Repair Hand]


name: Cream, Multi Ingredient Topical application Cream [Nivea Intense Healing]


name: Cream, Multi Ingredient Topical application Cream [Nivea Skin Toning & Firming Gel-Cream]


name: Ointment, Multi Ingredient Topical application Ointment [Nivea Men Sensitive Calm Face & Beard Balm]


name: Cream, Multi Ingredient Topical application Cream [Eucerin Face Skin Balance Day Cream]


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-10%-5%-10% Topical application Lotion [Coppertone Oil-Free+Shine Control Face]


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-9%-4.5%-9% Topical application Lotion [Coppertone Every Tone Sunscreen]


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-10%-5%-5% Topical application Lotion


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-7%-5%-5% Topical application Lotion


name: Formula, Infant Oral Powder for Suspension [Similac Alimentum Toddler]


name: Ethanol/Propylene Glycol/Sodium Citrate/Water 0.52 ML/1 VIAL-6 ML/1 VIAL-0.2 GM/1 VIAL Injection Solution [Hepzato Diluent]


name: Zinc Oxide 24% Topical application Lotion [Eucerin Sensitive Mineral Face Sunscreen]


name: Zinc Oxide 24.08% Topical application Lotion [Coppertone Kids Roll-On Sunscreen]


name: Cleanser Topical application Foam [Eucerin Hydrating Foaming Cleanser]


name: Ethanol/Propylene Glycol/Sodium Citrate/Water 0.52 ML/1 VIAL-6 ML/1 VIAL-0.2 GM/1 VIAL Injection Solution


name: Aluminum Chlorohydrate 18% Topical application Solution


name: Aluminum Zirconium Tetrachlorohydrex Gly 19% Topical application Stick


name: CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE 0.025 g in 50 mL / GLYCERIN 0.005 g in 50 mL / LINOLENIC ACID 0.00275 g in 50 mL / TROMETHAMINE 0.22 g in 50 mL / OCTOCRYLENE 1.8 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.0018 g in 50 mL / PROPYLENE GLYCOL 2.5 g in 50 mL / WATER 27.55 mL in 50 mL / FRAGRANCE 13576 0.3 g in 50 mL / CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) 0.075 g in 50 mL / .ALPHA.-TOCOPHEROL 0.006 g in 50 mL / POLY(METHYL METHACRYLATE; 450000 MW) 2.1 g in 50 mL / AVOBENZONE 1.8 g in 50 mL / TITANIUM DIOXIDE 0.425 g in 50 mL / PHENOXYETHANOL 0.35 g in 50 mL / POLYETHYLENE GLYCOL 400 0.14225 g in 50 mL / LINOLEIC ACID 0.49725 g in 50 mL / SILICON DIOXIDE 0.575 g in 50 mL / ANHYDROUS CITRIC ACID 0.00025 g in 50 mL / ASCORBYL PALMITATE 0.00125 g in 50 mL / ASCORBIC ACID 0.00025 g in 50 mL / OCTISALATE 1.8 g in 50 mL / BEMOTRIZINOL 1.45 g in 50 mL / DIMETHICONE 1.25 g in 50 mL / OCTINOXATE 3.5982 g in 50 mL / BUTYLENE GLYCOL 2.5 g in 50 mL / C20-22 ALCOHOLS 0.3375 g in 50 mL / CHLORPHENESIN 0.1 g in 50 mL TOPICAL CREAM [AnubisMed]


name: ALLANTOIN 0.05 g in 50 mL / ALOE VERA LEAF 2.5 g in 50 mL / FRAGRANCE 13576 0.225 g in 50 mL / GLYCERYL MONOSTEARATE 0.875 g in 50 mL / TROLAMINE 0.3 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.0535 g in 50 mL / PROPYLENE GLYCOL 1.996 g in 50 mL / CETYL ALCOHOL 0.0038 g in 50 mL / TROPOLONE 0.004 g in 50 mL / TOCOPHEROL 0.0004 g in 50 mL / DIMETHICONE 0.25 g in 50 mL / 1,2-HEXANEDIOL 0.198 g in 50 mL / IMIDUREA 0.15 g in 50 mL / CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE 0.25 g in 50 mL / CETEARYL ETHYLHEXANOATE 1.75 g in 50 mL / MEDIUM-CHAIN TRIGLYCERIDES 1.5 g in 50 mL / CAPRYLYL GLYCOL 0.198 g in 50 mL / OCTINOXATE 3.4965 g in 50 mL / GLYCERIN 0.4975 g in 50 mL / GLYCERYL STEARATE SE 1.5 g in 50 mL / WATER 27.4065 mL in 50 mL / C12-20 ACID PEG-8 ESTER 2.25 g in 50 mL / OXYBENZONE 2 g in 50 mL / DECYL OLEATE 1.9996 g in 50 mL TOPICAL CREAM [ANUBISMED]


name: GLYCOLIC ACID 17 g in 50 mL / KOJIC ACID 2.5 g in 50 mL / HEXYLRESORCINOL 1 g in 50 mL / ASCORBYL GLUCOSIDE 0.25 g in 50 mL / LACTIC ACID 5 g in 50 mL / PHENOXYETHANOL 0.225 g in 50 mL / PROPYLENE GLYCOL 0.5 g in 50 mL / HYDROXYETHYL CELLULOSE, UNSPECIFIED 0.34875 g in 50 mL / ALCOHOL 6.3 mL in 50 mL / AMMONIA 2.75 g in 50 mL / ISOPROPYL ALCOHOL 0.75 g in 50 mL / WATER 7.333 mL in 50 mL / ETHYLHEXYLGLYCERIN 0.025 g in 50 mL / SALICYLIC ACID 1 g in 50 mL TOPICAL LIQUID [AnubisMed]


name: IMIDUREA 0.25 g in 50 mL / ALOE VERA LEAF 0.15 g in 50 mL / WATER 45.8293 mL in 50 mL TOPICAL LIQUID [AnubisMed]


name: ZINC OXIDE 0.0135 g in 1 g TOPICAL CREAM [Sheer Protection SPF 30]


name: Easy Comfort 0.3ML 31G 5/16 inch Insulin Syringe


name: Easy Comfort 0.3mL 31G 1/2 inch Insulin Syringe


name: CVS TENS Muscle Pain Therapy Replacement Pad


name: Equate Nutritional Shake Plus (Chocolate)


name: OneTouch Delica Safety 30G Single Use Lancing Device


name: OneTouch Ultra2 Blood Glucose Monitoring System


name: OneTouch Verio Flex Blood Glucose Monitoring System


name: TRACH CANNULA,INNER 7MM SMITHS #101858080


name: BANDAGE KIT,COMPRESSION COFLEX TLC CALAMINE LITE


name: TUBE FEEDING SET,EXTENSION ENFIT AMT #8-1255-ISOSAF


name: DRESSING,COLACTIVE PLUS AG PKT,POWDER,TOP


name: BANDAGE TUBULAR ELASTIC TUBIFAST LARGE LIMB


name: VAD DRIVELINE MAINTENANCE KIT CENTURION #DT16130


name: DRESSING,ZETUVIT PLUS 4IN X 4IN #4131100


name: TRACH STOMA PROTECTOR,BUCHANAN LITE LUMINAUD #38232


name: BANDAGE,STRETCH,URGOK2 7 1/8IN X 9 3/4IN


name: protein hydrolysate/collagen, hydrolyzed 20 gram-120 kcal/37.5 mL ORAL LIQUID IN PACKET (ML)


name: silver/calcium alginate 12" TOPICAL BANDAGE


name: silver/silicone/foam bandage 2" X 2" TOPICAL BANDAGE


name: silver/silicone/foam bandage 6" X 6" TOPICAL BANDAGE


name: syringe,safety with needle,0.5 mL 30 gauge X 1/2" MISCELL SYRINGE, EMPTY DISPOSABLE


name: calcium alginate 4 1/4" X 4 1/4" TOPICAL BANDAGE


name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA


name: non-adherent bandage/sunflower oil/petrolatum,white 3" X 3" TOPICAL BANDAGE


name: non-adherent bandage/sunflower oil/petrolatum,white 3" X 8" TOPICAL BANDAGE


name: non-adherent bandage/sunflower oil/petrolatum,white 5" X 9" TOPICAL BANDAGE


name: ALUMINUM SESQUICHLOROHYDRATE 250 mg in 1 mL TOPICAL STICK [Power Stick Invisible Protection Roll- On Antiperspirant Deodorant Spring Fresh]


name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Agent Natuer holi (sun) dewy tinted skin drops]


name: OCTISALATE 50 mg in 1 mL / ZINC OXIDE 40 mg in 1 mL TOPICAL CREAM [Brickell Mens Products Daily Defense Face Moisturizer SPF-20]


name: TITANIUM DIOXIDE 20 mg in 1 mL / ZINC OXIDE 170 mg in 1 mL TOPICAL CREAM [Mineral Creme SPF 50 Mineral Creme SPF 50 Broad Spectrum UVA-UVB Sunscreen Water Resistant (80 min)]


name: TITANIUM DIOXIDE 2 g in 100 g / ZINC OXIDE 17 g in 100 g TOPICAL CREAM [MD Mineral BB Creme Broad Spectrum SPF 50 Water Resistant (80min) Mineral Sunscreen DARK]


name: OXYBENZONE 6 g in 100 mL / OCTISALATE 5 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 2.7 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [Bee Bald Smooth Plus Daily Moisturizer SPF 30 Sunscreen]


name: TITANIUM DIOXIDE 81 mg in 1 g / ZINC OXIDE 60 mg in 1 g TOPICAL STICK [Solar SPF 40 Broad Spectrum SPF 40 Water Resistant (80 min) Mineral Suncreen]


name: PANTHENOL 0.501 g in 100 mL TOPICAL LIQUID [ReOrganic Eyelash Growth Boosting Serum]


name: Calcipotriene;Dimethicone 0.005%; 5% Topical application Cream [Calsodore Kit]


name: ZINC OXIDE 200 mg in 1 g TOPICAL LOTION [Baby Mineral Sunscreen Probiotics SPF55]


name: ZINC OXIDE 13.5 g in 100 g TOPICAL CREAM [Hale and Hush Broad Spectrum SPF 30 SPF 30]


name: Ethinyl Estradiol/Levonorgestrel;Ferrous Fumarate 0.02 MG-0.1 MG; 75 MG Oral Tablet


name: ZINC OXIDE 160 mg in 1 g / TITANIUM DIOXIDE 34 mg in 1 g TOPICAL SPRAY [Kids Mineral Sunscreen SPF50]


name: ZINC OXIDE 16.5 g in 100 mL TOPICAL LOTION [DAILY SUPERGOOP DOSE BIORETINOL MINERAL SPF 40]


name: NICOTINAMIDE MONONUCLEOTIDE 600 mg ORAL CAPSULE


name: Dimethicone;Mometasone Furoate 5%; 0.1% Multiple Routes Kit [Mometacure]


name: TITANIUM DIOXIDE 3.3 g in 100 mL / ZINC OXIDE 14.9 g in 100 mL TOPICAL LIQUID [NAKED SUNDAYS CABANA GLOW MINERAL GLOW SERUM DROPS BRONZE 40mL with wild Rosella SPF 50]


name: Zinc Oxide 160 mg in 1 g TOPICAL CREAM [Skin Apeel Ageless Defense SPF 40 Broad Spectrum]


name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 27.5 mg in 1 mL TOPICAL LOTION [Gleam plus Glow SPF 50. SPF 50 Broad Spectrum Sunscreen UVA-UVB Sheer Glow Tint]


name: ZINC OXIDE 250 mg in 1 g TOPICAL LOTION [earth mama UBER-SENSITIVE MINERAL Sunscreen SPF 40]


name: AVOBENZONE 30 mg in 1 g / OCTISALATE 50 mg in 1 g / HOMOSALATE 100 mg in 1 g TOPICAL LIPSTICK [Hydrating Sheer Lip Balm SPF 30 - BARE Broad Spectrum SPF 30 UVA-UVB Sunscreen]


name: HOMOSALATE 15 g in 100 g / OCTISALATE 5 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 10 g in 100 g TOPICAL SPRAY [SPF 50 Sunscreen Unfragranced]


name: NIACINAMIDE 5 g in 100 mL / ADENOSINE 0.04 g in 100 mL / ARBUTIN 5 g in 100 mL TOPICAL LIQUID [Reoganic EX Whitening Pore Care Deodorant]


name: TITANIUM DIOXIDE 16 g in 100 mL / OCTINOXATE 6.99 g in 100 mL TOPICAL CREAM [anna lotan Premium BB Cream SPF46 Medium Beige]


name: TITANIUM DIOXIDE 20 mg in 1 mL / ZINC OXIDE 170 mg in 1 mL TOPICAL CREAM [Mineral KidCreme SPF 50]


name: ZINC OXIDE 18 mg in 1 g TOPICAL CREAM [Prequel Sun Barrier Mineral Sunscreen Broad Spectrum SPF 50]


name: Nivea Intense Healing Moisture Body Cream


name: Audio-Video (Appendix P) and Audio-Only (Appendix T) Telemedicine Services Criteria


name: Multiple Evaluation and Management Services on the Same Date


name: New patient office or other outpatient visit with straightforward medical decision making, if using time, 15 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and straightforward medical decision making. If using time at least 15 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and straightforward medical decision making. If using time at least 15 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and straightforward medical decision making. If using time at least 15 minutes of total time on the date of the encounter must be met.


name: New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and low level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and low level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and low level of medical decision making. If using time at least 30 minutes of total time on the date of the encounter must be met.


name: New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and moderate level of medical decision making. If using time, at least 45 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and moderate level of medical decision making. If using time, at least 45 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and moderate level of medical decision making. If using time at least 45 minutes of total time on the date of the encounter must be met.


name: New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and high level of medical decision making. If using time, at least 60 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and high level of medical decision making. If using total time, at least 60 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and high level of medical decision making. If using total time, at least 60 minutes of total time on the date of the encounter must be met.


name: Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and straightforward medical decision making. If using time, at least 10 minutes of total time on encounter date must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and straightforward medical decision making. If using time, at least 10 minutes of total time on the encounter date must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and straightforward medical decision making. If using time, at least 10 minutes of total time on the encounter date must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and low level of medical decision making. If using time, at least 20 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and low level of medical decision making. If using time, at least 20 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and low level of medical decision making. If using time at least 20 minutes of total time on the date of the encounter must be met.


name: Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and moderate level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and moderate level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and moderate level of medical decision making. If using time at least 30 minutes of total time on the date of the encounter must be met.


name: Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and high level of medical decision making. If using time, at least 40 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and high level of medical decision making. If using time, at least 40 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and high level of medical decision making. If using time at least 40 minutes of total time on the date of the encounter must be met.


name: Initial nursing facility care with high level of medical decision making, per day, if using time, 50 minutes or more


name: Initial nursing facility care, per day, for evaluation and management of patient requiring medically appropriate examination and high level of medical decision making. If using time, at least 50 minutes total time on encounter date must be met.


name: Initial nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and examination and high level of medical decision making. If using time, at least 50 minutes total time on encounter date must be met.


name: Initial nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and high level of medical decision making. If using time, at least 50 minutes total time on encounter date must be met.


name: Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, 20 minutes or more


name: Subsequent nursing facility care, per day, for evaluation and management of patient requiring medically appropriate examination and low level of medical decision making. If using time, at least 20 minutes total time on encounter date must be met.


name: Subsequent nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and examination and low level of medical decision making. If using time, at least 20 minutes total time on encounter date must be met.


name: Subsequent nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and low level of medical decision making. If using time, at least 20 minutes total time on encounter date must be met.


name: Anterior thoracic vertebral body tethering, including thoracoscopy, when performed


name: Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; up to 7 vertebral segments


name: Tethering of 7 or fewer middle spine bones


name: Anterior thoracic vertebral body tethering with thoracoscopy, 7 or fewer vertebral segments


name: Anterior thoracic vertebral body tethering, 7 or fewer vertebral segments


name: Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; 8 or more vertebral segments


name: Tethering of 8 or more middle spine bones


name: Anterior thoracic vertebral body tethering with thoracoscopy, 8 or more vertebral segments


name: Anterior thoracic vertebral body tethering, 8 or more vertebral segments


name: Revision (eg, augmentation, division of tether), replacement, or removal of thoracic vertebral body tethering, including thoracoscopy, when performed


name: Revision, replacement, or removal of middle spine tethering


name: Augmentation of thoracic vertebral body tethering


name: Augmentation of thoracic vertebral body tethering with thoracoscopy


name: Division of thoracic vertebral body tethering


name: Division of thoracic vertebral body tethering with thoracoscopy


name: Removal of thoracic vertebral body tethering


name: Removal of thoracic vertebral body tethering with thoracoscopy


name: Replacement of thoracic vertebral body tethering


name: Replacement of thoracic vertebral body tethering with thoracoscopy


name: Revision of thoracic vertebral body tethering


name: Revision of thoracic vertebral body tethering with thoracoscopy


name: Arthrodesis, sacroiliac joint, percutaneous or minimally invasive, with image guidance, includes obtaining bone graft when performed, unilateral; placement of intra-articular device(s), without cortical piercing


name: Correction of hallux vagus with bunionectomy and resection of proximal phalanx base


name: Correction of hallux vagus with bunionectomy and sesamoidectomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and resection of proximal phalanx base


name: Correction of hallux vagus with bunionectomy and distal metatarsal osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and distal metatarsal osteotomy


name: Correction of hallux vagus with bunionectomy and proximal metatarsal osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and proximal metatarsal osteotomy


name: Correction of bunion with forefoot and midfoot bone fusion


name: Correction of hallux vagus with bunionectomy and first metatarsal and medial cuneiform joint arthrodesis


name: Correction of hallux vagus with bunionectomy, with sesamoidectomy and first metatarsal and medial cuneiform joint arthrodesis


name: Correction of hallux vagus with bunionectomy and proximal phalanx osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and proximal phalanx osteotomy


name: Correction of hallux vagus with bunionectomy and double osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and double osteotomy


name: Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve


name: Destruction of nasal nerve by heat using an endoscope


name: Surgical nasal endoscopy with destruction of posterior nasal nerve by radiofrequency ablation


name: Surgical sinus endoscopy with destruction of posterior nasal nerve by radiofrequency ablation


name: Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve


name: Destruction of nasal nerve by freezing using an endoscope


name: Surgical nasal endoscopy with destruction of posterior nasal nerve by cryoablation


name: Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed


name: Insertion of phrenic nerve stimulator generator and stimulating lead(s)


name: Insertion of pulse generator and stimulating leads of phrenic nerve stimulator system


name: Insertion of pulse generator and stimulating leads of phrenic nerve stimulator system, including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation


name: Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)


name: Insertion of phrenic nerve stimulator sensing lead


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)


name: Removal of phrenic nerve stimulator generator and lead(s)


name: Removal of phrenic nerve stimulator system, including pulse generator and lead(s)


name: Removal of phrenic nerve stimulator system, including pulse generator and lead(s), including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only


name: Removal of phrenic nerve stimulator stimulation or sensing lead(s)


name: Removal of phrenic nerve stimulator sensing lead(s) only


name: Removal of phrenic nerve stimulator sensing lead(s) only, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator transvenous stimulation lead(s) only


name: Removal of phrenic nerve stimulator transvenous stimulation lead(s) only, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator transvenous stimulation or sensing lead(s) only


name: Removal of phrenic nerve stimulator transvenous stimulation or sensing lead(s) only, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only


name: Removal of phrenic nerve stimulator pulse generator


name: Removal of phrenic nerve stimulator pulse generator, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Repositioning of phrenic nerve stimulator transvenous lead(s)


name: Repositioning of phrenic nerve stimulator lead(s)


name: Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator


name: Removal and replacement of phrenic nerve stimulator pulse generator


name: Removal and replacement of phrenic nerve stimulator pulse generator, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)


name: Removal and replacement of phrenic nerve stimulator stimulation or sensing leads


name: Removal and replacement of phrenic nerve stimulator sensing lead(s)


name: Removal and replacement of phrenic nerve stimulator sensing lead(s), including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal and replacement of phrenic nerve stimulator transvenous stimulation lead(s)


name: Removal and replacement of phrenic nerve stimulator transvenous stimulation lead(s), including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal and replacement of phrenic nerve stimulator transvenous stimulation or sensing lead(s)


name: Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed


name: Drug delivery using a drug-coated balloon for male treatment of urethral stricture using an endoscope


name: Cystourethroscopy with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for male urethral stricture or stenosis


name: Cystourethroscopy with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for male urethral stricture or stenosis with fluoroscopy


name: Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency


name: Destruction of uterine fibroid(s) using heat with ultrasound guidance and monitoring


name: Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including craniectomy or craniotomy, when performed, with direct or inductive coupling, with connection to depth and/or cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator pulse generator or receiver


name: Insertion of skull-mounted cranial neurostimulator with direct coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator with direct coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator with inductive coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator with inductive coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with direct coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with direct coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with inductive coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with inductive coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with direct coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with direct coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with inductive coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with inductive coupling and connection to depth strip electrode array(s)


name: Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s)


name: Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver


name: Replacement of skull-mounted cranial neurostimulator pulse generator with connection to cortical strip electrode array


name: Replacement of skull-mounted cranial neurostimulator pulse generator with connection to depth strip electrode array


name: Replacement of skull-mounted cranial neurostimulator receiver with connection to cortical strip electrode array


name: Replacement of skull-mounted cranial neurostimulator receiver with connection to depth strip electrode array


name: Revision of skull-mounted cranial neurostimulator pulse generator with connection to cortical strip electrode array


name: Revision of skull-mounted cranial neurostimulator pulse generator with connection to depth strip electrode array


name: Revision of skull-mounted cranial neurostimulator receiver with connection to cortical strip electrode array


name: Revision of skull-mounted cranial neurostimulator receiver with connection to depth strip electrode array


name: Removal of skull-mounted cranial neurostimulator pulse generator or receiver with cranioplasty, when performed


name: Removal of skull-mounted cranial neurostimulator pulse generator or receiver


name: Removal of skull-mounted cranial neurostimulator pulse generator


name: Removal of skull-mounted cranial neurostimulator pulse generator with cranioplasty


name: Removal of skull-mounted cranial neurostimulator receiver


name: Removal of skull-mounted cranial neurostimulator with cranioplasty


name: Insertion or replacement of spinal neurostimulator generator or receiver


name: Insertion of spinal neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of spinal neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of spinal neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of spinal neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Removal or revision of spinal neurostimulator generator or receiver


name: Removal of implanted spinal neurostimulator pulse generator with detachable electrode array


name: Removal of implanted spinal neurostimulator receiver with detachable connection to electrode array


name: Revision of implanted neurostimulator receiver with detachable connection to electrode array


name: Revision of implanted spinal neurostimulator pulse generator with detachable connection to electrode array


name: Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver


name: Insertion of gastric neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of gastric neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Insertion of peripheral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of peripheral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Insertion of sacral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of sacral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of gastric neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of gastric neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of peripheral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of peripheral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of sacral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of sacral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Removal or revision of a peripheral, sacral, or gastric neurostimulator pulse generator or receiver


name: Removal of gastric neurostimulator pulse generator, with detachable connection to electrode array


name: Removal of gastric neurostimulator receiver, with detachable connection to electrode array


name: Removal of peripheral neurostimulator pulse generator, with detachable connection to electrode array


name: Removal of peripheral neurostimulator receiver, with detachable connection to electrode array


name: Removal of sacral neurostimulator pulse generator, with detachable connection to electrode array


name: Removal of sacral neurostimulator receiver, with detachable connection to electrode array


name: Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed


name: Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array


name: Insertion or replacement of a peripheral integrated neurostimulator initial electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous initial electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous initial electrode array, including imaging guidance


name: Replacement of peripheral nerve integrated neurostimulator percutaneous initial electrode array


name: Replacement of peripheral nerve integrated neurostimulator percutaneous initial electrode array, including imaging guidance


name: Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)


name: Insertion or replacement of a peripheral integrated neurostimulator each additional electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous each additional electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous each additional electrode array, including imaging guidance


name: Replacement of peripheral nerve integrated neurostimulator percutaneous each additional electrode array


name: Replacement of peripheral nerve integrated neurostimulator percutaneous each additional electrode array, including imaging guidance


name: Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator


name: Revision or removal of a electrode array with an integrated neurostimulator


name: Removal of peripheral nerve neurostimulator electrode array, with integrated neurostimulator


name: Revision of peripheral nerve neurostimulator electrode array, with integrated neurostimulator


name: Suprachoroidal space injection of pharmacologic agent (separate procedure)


name: Injection of drug into the space between the cornea and retina in the eye


name: Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional


name: Ultrasound, intraoperative thoracic aorta (eg, epiaortic), diagnostic


name: Ultrasound of chest aorta during surgery


name: Diagnostic intraoperative epiaortic ultrasound


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; including placement and manipulation of transducer, image acquisition, interpretation and report


name: Ultrasound of heart during surgery to evaluate for congenital heart disease, including placement and manipulation of transducer, image acquisition, and interpretation and report of results


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; placement, manipulation of transducer, and image acquisition only


name: Ultrasound of heart during surgery to evaluate for congenital heart disease, including placement and manipulation of transducer and image acquisition


name: Diagnostic intraoperative epicardial cardiac echocardiography, placement, manipulation of transducer, and image acquisition only


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; interpretation and report only


name: Ultrasound of heart during surgery to evaluate for congenital heart disease, interpretation and report of results only


name: AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis


name: AF2/FMR2 gene analysis for detection of expanded alleles


name: Fragile X intellectual disability gene analysis for detection of abnormal alleles


name: Fragile X intellectual disability gene analysis for detection of expanded alleles


name: AF2/FMR2 gene analysis for evaluation of expanded size and methylation status of alleles


name: Fragile X intellectual disability gene analysis for characterization of alleles


name: Fragile X intellectual disability gene analysis for evaluation of expanded size and methylation status of alleles


name: FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis


name: Gene analysis (fragile X syndrome, X-linked intellectual disability) for detection of abnormal alleles


name: FMR1 gene analysis evaluation to detect expanded alleles


name: Fragile X syndrome gene analysis to detect abnormal alleles


name: Fragile X syndrome gene analysis to detect expanded alleles


name: X-linked intellectual gene analysis to detect abnormal alleles


name: X-linked intellectual gene analysis to detect expanded alleles


name: Gene analysis (fragile X syndrome, X-linked intellectual disability) for characterization of alleles


name: FMR1 gene analysis for evaluation of expanded size and promoter methylation status of alleles


name: Fragile X ribonucleoprotein 1 gene analysis evaluation of expanded size and promoter methylation status of alleles


name: Fragile X syndrome gene analysis for characterization of alleles


name: Fragile X syndrome gene analysis for evaluation of expanded size and promoter methylation status of alleles


name: X-linked intellectual disability gene analysis for characterization of alleles


name: X-linked intellectual disability gene analysis for evaluation of expanded size and promoter methylation status of alleles


name: Molecular pathology procedure level 4 genetic analysis


name: Level 4 molecular analysis -targeted sequence analysis of exon 7 of fibroblast growth factor receptor 3 (FGFR3) for evaluation of isolated craniosynostosis


name: Level 4 molecular pathology procedure - Analysis of more than 10 amplicons using multiplex PCR in 2 or more independent reactions


name: Level 4 molecular pathology procedure - Analysis of single exon by DNA sequence analysis


name: Level 4 molecular pathology procedure - Angiogenin, ribonuclease, RNase A family (ANG) full gene sequence analysis


name: Level 4 molecular pathology procedure - Coagulation factor VIII (F8), inversion analysis of intron 1


name: Level 4 molecular pathology procedure - Coagulation factor VIII (F8), inversion analysis of intron 22A


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Deletion analysis Rh blood group, D antigen (RHD) of pseudogene for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Epithelial cell adhesion molecule (EPCAM) for evaluation of Lynch syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 for Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of SH2 domain containing 1A (SH2D1A) for evaluation of X-linked lymphoproliferative syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of Von Hippel-Lindau tumor suppressor (VHL) for evaluation of Hippel-Lindau familial cancer syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of aristaless-related homeobox (ARX) for evaluation of X-linked intellectual disability


name: Level 4 molecular pathology procedure - Deletion analysis of aristaless-related homeobox (ARX) for evaluation of X-linked lissencephaly with ambiguous genitalia


name: Level 4 molecular pathology procedure - Deletion analysis of paired-like homeobox 2b (PHOX2B)for evaluation of congenital central hypoventilation syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of twist homolog 1 [Drosophila] (TWIST1) for evaluation of Saethre-Chotzen syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of SH2 domain containing 1A (SH2D1A) for evaluation of X-linked lymphoproliferative syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of Von Hippel-Lindau tumor suppressor (VHL) for evaluation of Hippel-Lindau familial cancer syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of aristaless-related homeobox (ARX) for evaluation of X-linked intellectual disability


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of twist homolog 1 [Drosophila] (TWIST1)for evaluation of Saethre-Chotzen syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication of aristaless-related homeobox (ARX) analysis for evaluation of X-linked lissencephaly with ambiguous genitalia


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Duffy blood group (DARC) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Duplication analysis of SH2 domain containing 1A (SH2D1A) for evaluation of X-linked lymphoproliferative syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of Von Hippel-Lindau tumor suppressor (VHL) for evaluation of Hippel-Lindau familial cancer syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of aristaless-related homeobox (ARX) for evaluation of X-linked intellectual disability


name: Level 4 molecular pathology procedure - Duplication analysis of aristaless-related homeobox (ARX) for evaluation of X-linked lissencephaly with ambiguous genitalia


name: Level 4 molecular pathology procedure - Duplication analysis of epithelial cell adhesion molecule (EPCAM) for evaluation of Lynch syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of paired-like homeobox 2b (PHOX2B)for evaluation of congenital central hypoventilation syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of twist homolog 1 [Drosophila] (TWIST1) for evaluation of Saethre-Chotzen syndrome


name: Level 4 molecular pathology procedure - Duplication and deletion analysis of epithelial cell adhesion molecule (EPCAM) for evaluation of Lynch syndrome


name: Level 4 molecular pathology procedure - Duplication and deletion analysis of paired-like homeobox 2b (PHOX2B) for evaluation of congenital central hypoventilation syndrome


name: Level 4 molecular pathology procedure - Duplication and deletion analysis of variants of 2-5 exons


name: Level 4 molecular pathology procedure - Exon 2 sequence analysis of v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) for evaluation of Costello syndrome


name: Level 4 molecular pathology procedure - Full gene sequence analysis of mitochondrially encoded 12S RNA (MT-RNR1) for evaluation of nonsyndromic hearing loss


name: Level 4 molecular pathology procedure - Full gene sequence analysis of phospholamban (PLN) for evaluation of dilated cardiomyopathy


name: Level 4 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11for evaluation of familial hyperinsulinism


name: Level 4 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 2 (KCNJ2) for evaluation of Andersen-Tawil syndrome


name: Level 4 molecular pathology procedure - Full gene sequence of NHL repeat containing 1 (NHLRC1) for evaluation of progressive myoclonal epilepsy


name: Level 4 molecular pathology procedure - Gene analysis for common deletions of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFa deletion of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFb deletion for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFc deletion of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFd deletion of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis of MHC class I polypeptide-related sequence A (MICA) for detection of *001 variant in solid organ transplantation


name: Level 4 molecular pathology procedure - Gene analysis of MHC class I polypeptide-related sequence A (MICA) for detection of *002 variant in solid organ transplantation


name: Level 4 molecular pathology procedure - Gene analysis of MHC class I polypeptide-related sequence A (MICA) for detection of common variants in solid organ transplantation


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of Q209 variant for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of R183 and Q209 variants for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of R183 variant for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of common variants for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with sickle-cell disease


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with thalassemia


name: Level 4 molecular pathology procedure - Inversion analysis of intron 1 and intron 22A of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 4 molecular pathology procedure - Inversion analysis of intron 1 of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 4 molecular pathology procedure - Inversion analysis of intron 22A of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of thalassemia


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Mutation scanning of 2-5 exons


name: Level 4 molecular pathology procedure - Potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) full gene sequence analysis


name: Level 4 molecular pathology procedure - Potassium inwardly-rectifying channel, subfamily J, member 2 (KCNJ2) full gene sequence analysis


name: Level 4 molecular pathology procedure - Potassium voltage-gated channel, Shaw-related subfamily, member 3 (KCNC3) targeted sequence analysis


name: Level 4 molecular pathology procedure - Potassium voltage-gated channel, Shaw-related subfamily, member 3 (KCNC3) targeted sequence analysis of exon 2